A new study points to the protein TRIM21 as a key driver of pancreatic adenocarcinoma (PAAD), one of the deadliest cancers with a 5-year survival rate below 9%. Using bioinformatics and lab experiments, researchers found that TRIM21 is highly overexpressed in pancreatic cancer tissues and strongly linked to poor patient outcomes.
High levels of TRIM21 were associated with shorter disease-free survival and increased immune cell infiltration in tumors, suggesting that the protein promotes cancer growth and may serve as a biomarker. When scientists reduced TRIM21 levels in pancreatic cancer cells, tumor growth, proliferation, and migration were significantly slowed, while cell death increased.
Further investigation revealed that TRIM21 drives cancer progression by activating the Wnt/β-catenin signaling pathway, a key regulator of tumor development. Blocking TRIM21 suppressed this pathway and halted cancer cell growth.
The findings identify TRIM21 as a potential therapeutic target for pancreatic adenocarcinoma, offering a new direction for drug development against this aggressive disease.